LON:AZN - AstraZeneca Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 5,454 0.00 (0.00 %)
(As of 05/24/2018 02:33 AM ET)
Previous CloseGBX 5,454
Today's RangeGBX 5,418 - GBX 5,502
52-Week RangeGBX 4,260 - GBX 5,520
Volume2.93 million shs
Average Volume2.31 million shs
Market Capitalization£61.66 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About AstraZeneca (LON:AZN)

AstraZeneca logoAstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:AZN
CUSIPN/A
Phone+44-20-73045000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins21.83%
Return on Equity36.38%
Return on Assets7.91%

Miscellaneous

EmployeesN/A
Outstanding Shares1,270,000,000

AstraZeneca (LON:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a dividend on Friday, February 2nd. Stockholders of record on Thursday, February 15th will be given a dividend of GBX 133.60 per share on Monday, March 19th. This represents a dividend yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 15th. This is a boost from AstraZeneca's previous dividend of $68.90. The official announcement can be seen at this link. View AstraZeneca's Dividend History.

What price target have analysts set for AZN?

23 brokerages have issued 12 month target prices for AstraZeneca's shares. Their forecasts range from GBX 3,750 to GBX 6,500. On average, they expect AstraZeneca's stock price to reach GBX 5,304.05 in the next year. View Analyst Ratings for AstraZeneca.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, Exec. Director & CEO (Age 59)
  • Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Has AstraZeneca been receiving favorable news coverage?

News articles about AZN stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AstraZeneca earned a news impact score of 0.21 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of AstraZeneca?

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately GBX 5,454.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of £61.66 billion.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.


MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  1,117 (Vote Outperform)
Underperform Votes:  1,378 (Vote Underperform)
Total Votes:  2,495
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AstraZeneca (LON:AZN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
23 Wall Street analysts have issued ratings and price targets for AstraZeneca in the last 12 months. Their average twelve-month price target is GBX 5,304.05The high price target for AZN is GBX 6,500 and the low price target for AZN is GBX 3,750. There are currently 3 sell ratings, 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyHoldHold
Consensus Rating Score: 2.482.522.482.41
Ratings Breakdown: 3 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 5,304.05GBX 5,274.68GBX 5,251.27GBX 5,189.43

AstraZeneca (LON:AZN) Consensus Price Target History

Price Target History for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/24/2018Liberum CapitalReiterated RatingHoldView Rating Details
5/23/2018CfraSet Price TargetNeutralGBX 5,000View Rating Details
5/22/2018Morgan StanleySet Price TargetNeutralGBX 5,250View Rating Details
5/22/2018BarclaysSet Price TargetBuyGBX 6,500View Rating Details
5/21/2018Sanford C. BernsteinUpgradeOutperformGBX 5,673 ➝ GBX 6,026View Rating Details
5/21/2018Deutsche BankReiterated RatingBuyView Rating Details
5/21/2018JPMorgan Chase & Co.Set Price TargetBuyGBX 5,500View Rating Details
5/18/2018Berenberg BankReiterated RatingBuyGBX 6,000View Rating Details
5/18/2018Goldman Sachs GroupSet Price TargetSellGBX 3,750View Rating Details
5/18/2018UBSSet Price TargetNeutralGBX 4,550View Rating Details
5/18/2018Shore CapitalReiterated RatingHoldView Rating Details
5/14/2018Jefferies GroupReiterated RatingBuyView Rating Details
5/4/2018Credit Suisse GroupReiterated RatingOutperformView Rating Details
3/22/2018BNP ParibasReiterated RatingOutperformGBX 5,600View Rating Details
3/14/2018Societe GeneraleReiterated RatingBuyView Rating Details
3/1/2018CitigroupReiterated RatingBuyGBX 6,200View Rating Details
2/6/2018Kepler Capital MarketsBoost Price TargetBuyGBX 5,250 ➝ GBX 5,300View Rating Details
12/15/2017Bryan, Garnier & CoReiterated RatingBuyView Rating Details
11/16/2017HSBCBoost Price TargetReduceGBX 4,340 ➝ GBX 4,380View Rating Details
11/10/2017S&P GlobalSet Price TargetNeutralGBX 5,000View Rating Details
11/6/2017InvestecBoost Price TargetBuyGBX 4,900 ➝ GBX 5,500View Rating Details
9/6/2017NatixisUpgradeNeutral ➝ BuyGBX 5,000 ➝ GBX 5,738View Rating Details
7/28/2017Beaufort SecuritiesDowngradeSellGBX 3,900View Rating Details
6/24/2016Independent ResearchSet Price TargetSellGBX 3,650View Rating Details
(Data available from 5/24/2016 forward)

Earnings

Dividends

AstraZeneca (LON:AZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/2/2018GBX 133.602.8%2/15/20182/15/20183/19/2018
7/27/2017GBX 68.901.35%8/10/20178/10/20179/11/2017
2/2/2017GBX 150.203.52%2/16/20172/16/20173/20/2017
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

AstraZeneca (LON AZN) Insider Trading and Institutional Ownership History

Insider Trading History for AstraZeneca (LON:AZN)

AstraZeneca (LON AZN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/2/2018Philip A J BroadleyInsiderBuy415GBX 4,846£20,110.90
7/27/2017Nazneen RahmanInsiderBuy39GBX 4,370£1,704.30
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)

Headlines

AstraZeneca (LON AZN) News Headlines

Source:
DateHeadline
AstraZeneca (AZN) Given a GBX 5,000 Price Target by Cfra AnalystsAstraZeneca (AZN) Given a GBX 5,000 Price Target by Cfra Analysts
www.americanbankingnews.com - May 23 at 6:30 PM
Drug Overview & Outlook for Seroquel/Seroquel XR (AstraZeneca, Kyowa Pharmaceutical) 2017-2018 to 2026 with ...Drug Overview & Outlook for Seroquel/Seroquel XR (AstraZeneca, Kyowa Pharmaceutical) 2017-2018 to 2026 with ...
www.prnewswire.com - May 23 at 5:28 PM
AstraZeneca (AZN) Given a GBX 6,500 Price Target by Barclays AnalystsAstraZeneca (AZN) Given a GBX 6,500 Price Target by Barclays Analysts
www.americanbankingnews.com - May 22 at 9:47 AM
Morgan Stanley Analysts Give AstraZeneca (AZN) a GBX 5,250 Price TargetMorgan Stanley Analysts Give AstraZeneca (AZN) a GBX 5,250 Price Target
www.americanbankingnews.com - May 22 at 9:45 AM
U.K. stocks log record close as U.S.-China ease trade-war tensionsU.K. stocks log record close as U.S.-China ease trade-war tensions
finance.yahoo.com - May 21 at 5:06 PM
Edited Transcript of AZN.L earnings conference call or presentation 18-May-18 11:00am GMTEdited Transcript of AZN.L earnings conference call or presentation 18-May-18 11:00am GMT
finance.yahoo.com - May 21 at 5:06 PM
AstraZeneca Gets FDA Nod for Hyperkalaemia DrugAstraZeneca Gets FDA Nod for Hyperkalaemia Drug
finance.yahoo.com - May 21 at 5:06 PM
AstraZenecas (AZN) "Buy" Rating Reiterated at Deutsche BankAstraZeneca's (AZN) "Buy" Rating Reiterated at Deutsche Bank
www.americanbankingnews.com - May 21 at 10:00 AM
AstraZeneca (AZN) Upgraded to Outperform by Sanford C. BernsteinAstraZeneca (AZN) Upgraded to Outperform by Sanford C. Bernstein
www.americanbankingnews.com - May 21 at 9:55 AM
AstraZeneca (AZN) Given a GBX 5,500 Price Target by JPMorgan Chase AnalystsAstraZeneca (AZN) Given a GBX 5,500 Price Target by JPMorgan Chase Analysts
www.americanbankingnews.com - May 21 at 9:14 AM
AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?
finance.yahoo.com - May 19 at 5:42 PM
BRIEF-Astrazeneca Says US FDA Approved Lokelma In US For Treatment Of Adults With HyperkalaemiaBRIEF-Astrazeneca Says US FDA Approved Lokelma In US For Treatment Of Adults With Hyperkalaemia
www.reuters.com - May 18 at 5:51 PM
UK stocks fall from record as AstraZeneca, oil stocks declineUK stocks fall from record as AstraZeneca, oil stocks decline
www.marketwatch.com - May 18 at 5:51 PM
AstraZeneca Group plc 2018 Q1 - Results - Earnings Call SlidesAstraZeneca Group plc 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 18 at 5:51 PM
AstraZeneca: appliance of scienceAstraZeneca: appliance of science
www.ft.com - May 18 at 5:51 PM
UK stocks fall from record as AstraZeneca, mining stocks declineUK stocks fall from record as AstraZeneca, mining stocks decline
www.marketwatch.com - May 18 at 5:51 PM
Berenberg Bank Reiterates "Buy" Rating for AstraZeneca (AZN)Berenberg Bank Reiterates "Buy" Rating for AstraZeneca (AZN)
www.americanbankingnews.com - May 18 at 4:37 PM
AstraZeneca (AZN) PT Set at GBX 4,550 by UBSAstraZeneca (AZN) PT Set at GBX 4,550 by UBS
www.americanbankingnews.com - May 18 at 4:13 PM
AstraZeneca (AZN) PT Set at GBX 3,750 by Goldman SachsAstraZeneca (AZN) PT Set at GBX 3,750 by Goldman Sachs
www.americanbankingnews.com - May 18 at 4:13 PM
AstraZeneca (AZN) Stock Rating Reaffirmed by Liberum CapitalAstraZeneca (AZN) Stock Rating Reaffirmed by Liberum Capital
www.americanbankingnews.com - May 18 at 1:18 PM
AstraZeneca (AZN) Stock Rating Reaffirmed by Shore CapitalAstraZeneca (AZN) Stock Rating Reaffirmed by Shore Capital
www.americanbankingnews.com - May 18 at 1:18 PM
Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?
finance.yahoo.com - May 17 at 6:17 PM
MPs call for post-Brexit pharmaceutical deal with EUMPs call for post-Brexit pharmaceutical deal with EU
finance.yahoo.com - May 17 at 8:29 AM
AstraZeneca (AZN) Receives Average Recommendation of "Hold" from AnalystsAstraZeneca (AZN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 17 at 5:29 AM
AstraZeneca (AZN) Earns "Overweight" Rating from JPMorgan ChaseAstraZeneca (AZN) Earns "Overweight" Rating from JPMorgan Chase
www.americanbankingnews.com - May 15 at 11:56 AM
How Do Analysts See AstraZeneca PLC (LON:AZN) Performing In The Years Ahead?How Do Analysts See AstraZeneca PLC (LON:AZN) Performing In The Years Ahead?
finance.yahoo.com - May 14 at 5:15 PM
The Week Ahead: Coindesk Conference, Walmart And Retailers Close Out Earnings SeasonThe Week Ahead: Coindesk Conference, Walmart And Retailers Close Out Earnings Season
finance.yahoo.com - May 14 at 5:15 PM
AstraZeneca (AZN) PT Set at GBX 5,950 by Jefferies GroupAstraZeneca (AZN) PT Set at GBX 5,950 by Jefferies Group
www.americanbankingnews.com - May 14 at 10:39 AM
AstraZeneca (AZN) PT Set at GBX 6,500 by BarclaysAstraZeneca (AZN) PT Set at GBX 6,500 by Barclays
www.americanbankingnews.com - May 11 at 6:33 PM
AstraZenecas Symbicort ([budesonide + formoterol]) Overview 2018 - ResearchAndMarkets.comAstraZeneca's Symbicort ([budesonide + formoterol]) Overview 2018 - ResearchAndMarkets.com
www.businesswire.com - May 11 at 5:48 PM
Shore Capital Reiterates "Hold" Rating for AstraZeneca (AZN)Shore Capital Reiterates "Hold" Rating for AstraZeneca (AZN)
www.americanbankingnews.com - May 11 at 9:56 AM
FTSE 100 set to extend winning streak as bid for ZPG fuels M&A trendFTSE 100 set to extend winning streak as bid for ZPG fuels M&A trend
finance.yahoo.com - May 11 at 8:37 AM
BRIEF-Luye Pharma Group Acquires Astrazenecas Rights Relating To Seroquel And Seroquel XRBRIEF-Luye Pharma Group Acquires Astrazeneca's Rights Relating To Seroquel And Seroquel XR
www.reuters.com - May 7 at 5:32 PM
AstraZeneca shareholders urged to reject pay reportAstraZeneca shareholders urged to reject pay report
www.ft.com - May 7 at 5:32 PM
AstraZeneca (AZN) Given "Outperform" Rating at Credit Suisse GroupAstraZeneca (AZN) Given "Outperform" Rating at Credit Suisse Group
www.americanbankingnews.com - May 5 at 1:07 AM
PARP Inhibitors Cancer Therapy Market, 2023 - Lynpraza (Olaparib) by AstraZeneca was One of the Most Profitable ...PARP Inhibitors Cancer Therapy Market, 2023 - Lynpraza (Olaparib) by AstraZeneca was One of the Most Profitable ...
www.prnewswire.com - May 2 at 5:30 PM
PARP Drugs Help Some Metastatic Breast Cancer Patients, But Theyre No Magic BulletPARP Drugs Help Some Metastatic Breast Cancer Patients, But They're No Magic Bullet
finance.yahoo.com - April 30 at 5:09 PM
What You Must Know About AstraZeneca PLC’s (LON:AZN) ROEWhat You Must Know About AstraZeneca PLC’s (LON:AZN) ROE
finance.yahoo.com - April 26 at 5:12 PM
AstraZenecas (AZN) "Overweight" Rating Reiterated at JPMorgan ChaseAstraZeneca's (AZN) "Overweight" Rating Reiterated at JPMorgan Chase
www.americanbankingnews.com - April 25 at 10:25 AM
AstraZeneca raises stake in respiratory partner CircassiaAstraZeneca raises stake in respiratory partner Circassia
www.reuters.com - April 24 at 5:30 PM
AstraZeneca (AZN) Given a GBX 3,750 Price Target by Goldman Sachs AnalystsAstraZeneca (AZN) Given a GBX 3,750 Price Target by Goldman Sachs Analysts
www.americanbankingnews.com - April 24 at 12:14 PM
AstraZeneca (AZN) Given "Hold" Rating at Liberum CapitalAstraZeneca (AZN) Given "Hold" Rating at Liberum Capital
www.americanbankingnews.com - April 24 at 11:34 AM
Berenberg Bank Reiterates GBX 6,000 Price Target for AstraZeneca (AZN)Berenberg Bank Reiterates GBX 6,000 Price Target for AstraZeneca (AZN)
www.americanbankingnews.com - April 24 at 8:58 AM
[$$] Third Rock Throws Support Behind New Biotech Player[$$] Third Rock Throws Support Behind New Biotech Player
finance.yahoo.com - April 24 at 8:24 AM
FDA Nods to AstraZenecas Tagrisso for First-Line NSCLC (revised)FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)
www.nasdaq.com - April 23 at 5:08 PM
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)
finance.yahoo.com - April 23 at 5:08 PM
AstraZeneca (AZN) Receives Average Rating of "Hold" from BrokeragesAstraZeneca (AZN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 22 at 5:48 AM
Shore Capital Reaffirms "Hold" Rating for AstraZeneca (AZN)Shore Capital Reaffirms "Hold" Rating for AstraZeneca (AZN)
www.americanbankingnews.com - April 20 at 7:28 PM
AstraZeneca Shares Are Looking Very Weak Right NowAstraZeneca Shares Are Looking Very Weak Right Now
www.benzinga.com - April 20 at 5:16 PM
UBS Reiterates GBX 5,150 Price Target for AstraZeneca (AZN)UBS Reiterates GBX 5,150 Price Target for AstraZeneca (AZN)
www.americanbankingnews.com - April 20 at 4:16 PM

SEC Filings

AstraZeneca (LON:AZN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

AstraZeneca (LON AZN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.